 |
Administrative
Office:
3400 Spruce Street
1 Founders Building
Philadelphia, PA 19104
Research Administrative Coordinator:
Diane McLaughlin
Administrative Telephone: 215-662-2037
Administrative Fax: 215-662-7476
Clinical Offices:
3400 Spruce Street
Ground Gates
Philadelphia, PA 19104
Clinical Telephone: 215-662-2037
Clinical Fax: 215-662-7476
Contact
Information (internal use only)
ali.naji@uphs.upenn.edu  |
| Dr.
Ali Naji is the J. William White Professor of Surgery,
director kidney/pancreas transplantation center at Penn, director
of the JDRF-Penn Islet Transplantation Program, and associate director
of the Institute for Diabetes, Obesity and Metabolism at the University
of Pennsylvania School of Medicine. Dr. Naji completed his clinical
residency and fellowship training in general, vascular and transplantation
surgery at the Hospital of the University of Pennsylvania in Philadelphia.
Dr. Naji has served on several NIH study sections including Surgery/Anesthesia/
Trauma, Immunological Sciences and Transplantation/Tolerance/Tumor
Immunology. He is an associate editor for the journals Transplantation,
Diabetes and Transplantation Immunology. His basic research efforts
have focused on the immunobiology of transplantation and immune
pathogenesis of autoimmune diabetes. Specifically his investigations
were the first to demonstrate the critical role of recurrent anti-beta
cell autoimmunity as a basis for the failure of islet transplantation
for treatment of Type 1 diabetes mellitus (T1D). Most recently,
his group's efforts have focused on the role of B lymphocytes in
the pathogenesis of T1D and organ transplant rejection demonstrating
the requisite role of B lymphocytes as antigen presenting cells
in the pathogenesis of islet inflammation and immunologic rejection.
Translation of his basic research in islet transplantation studies
have demonstrated the efficacy of B lymphocyte targeting for the
induction of islet allograft tolerance in diabetic non-human primates.
Dr. Naji and his group plan to determine the clinical efficacy of
B lymphocyte directed immunotherapy as part of the cooperative NIH
sponsored islet transplantation consortium. |